ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO267

Prevalence of Cisplatin-Induced Nephrotoxicity in an Inner-City Population in the Bronx, New York

Session Information

Category: Onconephrology

  • 1700 Onconephrology

Authors

  • Hammami, M Bakri, New York City Health and Hospitals Jacobi, Bronx, New York, United States
  • Gudino, Paola, New York City Health and Hospitals Jacobi, Bronx, New York, United States
  • Rodriguez Salazar, Juan Diego, New York City Health and Hospitals Jacobi, Bronx, New York, United States
  • Vegivinti, Charan Thej Reddy, New York City Health and Hospitals Jacobi, Bronx, New York, United States
  • Acharya, Anjali, New York City Health and Hospitals Jacobi, Bronx, New York, United States
Background

Cisplatin is a commonly used chemotherapeutic agent with known nephrotoxicity. Studies evaluating its nephrotoxicity in minorities are limited. We assessed the incidence of kidney injury among our adult patients receiving cisplatin.

Methods

Retrospective review of records for adult patients receiving cisplatin from Jan 2021 to Jan 2023 was conducted. Serum Creatinine (SCr) and estimated glomerular filtration rate (eGFR) were obtained at baseline and within 30 days after cycles 1, 2, and 3 of Cisplatin. KDIGO definition was used to diagnose AKI.

Results

Of the 47 patients included in the analysis, 51.1% were male (n=24), median (range) age was 58 years (19-78). 42.6% were Black (n=20), 21.3% White (n=10) and others consisting of Pacific Islanders, American Indians, and Asians represented 36.2% (n=17). 80% of whites were Hispanic. The median number of cisplatin cycles was 4 (range: 1-11). Median baseline eGFR and SCr was 99.7ml/min and 0.80 g/dl, respectively. Blacks had a mean baseline GFR of 86.1ml/min, while non-Blacks had a mean of 100.86 ml/min (t=2.223, p=0.031). The median eGFR and SCr at the last follow-up after cisplatin was 77.80 ml/min and 0.99 g/dl, respectively. 10.6% of the patients developed AKI after the first dose of Cisplatin. There was no statistically significant correlation between race, sex, BMI or the use of immune checkpoint inhibitors and development of AKI. Repeated measures ANOVA test was conducted to evaluate the change in patients’ creatinine when measured before cisplatin, after 1st, 2nd and 3rd cycle. The results indicated a statistically significant rise in creatinine level following cisplatin therapy [Wilks’ Lambda = 0.003, F (1, 26) = 13.7, η2 = 0.44].

Conclusion

Our retrospective study in a minority based, low socioeconomic status adult population highlights the progressive risk of kidney injury following each cycle of cisplatin therapy, indicating risk for chronic dose-dependent cisplatin-induced nephrotoxicity. Patients from low socioeconomic backgrounds and minority populations may be at higher risk for renal dysfunction and progression to CKD. Further prospective studies targeting this specific population are warranted to validate these findings and develop tailored interventions to reduce cisplatin-induced nephrotoxicity.